鱼腥草-金银花滴眼剂体内外抗病毒作用的药效学研究

Phamacodynamic Study on the Anti-viral Effects in Vitro and in Vivo of Eye Drop Prepared by Mixed Extract of Heartleaf Houttuynia and Lonicera Japonica

[目的]了解鱼腥草和金银花混合提取物制备的滴眼剂(HLD)体内外抗I型单纯疱疹病毒(HSV-1)和Ⅲ型腺病毒(ADV-3)的效果。[方法]建立HSV-1感染Vero细胞和ADV-3感染HeLa细胞的模型,以不同数量宿主细胞出现病变效应(CPE)为观察指标,了解不同浓度HLD体外抗病毒效果。建立HSV-1感染家兔眼结膜炎模型,观察不同浓度HLD体内抗病毒效果,病变眼结膜组织进行常规病理学检查。实验中用市售阿昔洛韦滴眼剂(ACV)为对照。[结果]HLD完全抑制HSV-1和ADV-3对宿主细胞CPE的最低浓度分别为32mg/ml和64mg/ml。经HLD治疗后,HSV-1感染的家兔眼结膜病理性炎症反应明显减弱甚至消失。1g/ml、3g/ml和6g/mlHLD治疗实验性家兔眼结膜炎有效率分别为50.0%、83.3%和100%,其中6g/mlHLD与ACV滴眼剂疗效比较无显著性差异。[结论]HLD具有一定的体外抗病毒作用和较强的体内抗病毒效果,具有开发为一种新型防治病毒性眼结膜炎新药的前景。

[Objective] To determine the effects against human simplex virus type I（HSV-1） and adenovirus type Ⅲ （ADV-3） antiviral in vitro and in vivo of eye drop prepared by mixed extract of Heartleaf houttuynia and Lonicera japonica. [Methods] By using different numbers of host cells with cytopathic effect（CPE） as the observation index, models of HSV-1 infected Vero cells and ADV-3 infected HeLa cells were established to determine the anti-viral effects in vitro of HLD with different dosages. Rabbit eye conjunctivitis model infected by HSV1 was established to observe the anti-viral effects in vivo of HLD with different dosages, and the biopsy specimens of pathogenic eye conjunctive tissue were examined by routine pathological methods. In these experiments, a commercial acilovir eye drop（ACV） was used as the control, [Results] The minimum dosages of HLD to completely inhibit the CPEs of HSV-1 and ADV-3,the host cells were 32 mg/ml and 64 mg/ml respectively. After treatment with HLD, the inflammatory reactions of rabbit eye conjunctivitis caused by HSV-1 infection were obviously weak or disappeared. The curative rates of 1, 3 and 6 g/ml HLD treating experimental rabbit eye conjunctivitis were 50.0%, 83.3% and 100% respectively. Furthermore, the curative effect using 6 g/ml HLD has no significant difference compared to that using ACV drop. [Conclusion] HLD has a certain anti-viral effect in vitro and a stronger anti-viral effect in vivo, indicating the potential of HLD for developing a new drug to prevent or treat viral eye conjunctivitis.